Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

News > All

Total search results: 16973 | Ordered by Source (ascending)
next pagenext page 1 2 3 ... 168 169 170  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
Waters Corporation. (7/25/11). "Press Release: Waters CE Marks In Vitro Diagnostic MassTrak Immunosuppressants XE Kit. Putting LC/MS/MS to Use for Therapeutic Drug Monitoring of Tacrolimus and Everolimus in Transplant Patients". Atlanta, GA. 2011-07-25
Waters Corporation. (7/26/10). "Press Release: Waters Corporation to Showcase Analytical Technology Solutions at American Association of Clinical Chemists 2010. Industry Workshop and Scientific Presentations". Anaheim, CA. 2010-07-26
Waters Corporation. (8/2/12). "Press Release: Waters and Nonlinear Dynamics to Co-develop Next Generation Research Solutions for Large-scale, Complex Data Sets". Milford, MA & Newcastle Upon Tyne. 2012-08-02
Waters Corporation. (8/2/18). "Press Release: Waters UNIFI Mass Spectrometry Data Acquisition Technology Now Compatible with Mass-MetaSite and WebMetabase". Milford, MA. 2018-08-02
Waters Corporation. (8/23/16). "Press Release: Waters and NIBRT Researchers Generate Reference Library for Released N-Glycans Labeled with RapiFluor-MS". Toronto, ON. 2016-08-23
Waters Corporation. (8/7/13). "Media Advisory: Waters Acquires Nonlinear Dynamics Ltd.". Milford, MA. 2013-08-07
Waters Corporation. (9/11/14). "Press Release: Waters Unveils Global Mass Spectrometry Headquarters in the UK's North West". Wilmslow. 2014-09-11
Wellcome Trust, The. (3/20/12). "Press Release: Wellcome Trust to Launch £200 Million Investment Business for Healthcare and Life Sciences". 2012-03-20
Wellcome Trust, The. (3/24/14). "Press Release: Research Funders Outline Steps to Prevent Re-identification of Anonymised Study Participants". 2014-03-24
Wellcome Trust, The. (7/10/18). "Press Release: Director’s Update. Taking Risks on Bold Idease". 2018-07-10
Wellington Partners. (3/26/13). "Press Release: Stuart Essig Joins Wellington Partners Life Science Team as Venture Partner". Munich. 2013-03-26
Wellington Partners. (5/25/14). "Press Release: Wellington Partners Leads Spin-off of Neuway Pharma from LSI. Wellington Partners Takes Lead in € 2.7 M Series A Financing ". Munich. 2014-05-25
Wellington Partners. (7/31/19). "Press Release: Wellington Partners Raises EUR 210 Million Life Science Fund". 2019-07-31
Werum IT Solutions AG. (3/1/17). "Press Release: Werum America Reinforces Key Account Relations with Experienced Pharma Manufacturing Specialist". Lüneburg & Parsippany, NJ. 2017-03-01
Werum IT Solutions AG. (5/16/19). "Press Release: Jens Woehlbier Assigned as New CEO of Werum IT Solutions". Lüneburg. 2019-05-16
Werum IT Solutions AG. (5/2/16). "Press Release: Pharma Tech Firms Werum IT Solutions and Zenith Technologies Announce Global MES Partnership". Lüneburg. 2016-05-02
Werum IT Solutions AG. (8/13/14). "Press Release: UNIGEN, Japan: – MES for Complex Biopharmaceutical Production Implemented in Only Four Months with Werum's PAS-X Out of the Box". Lüneburg. 2014-08-13
WFB Wirtschaftsförderung Bremen GmbH. (11/11). "Pressemitteilung: Projekt des Monats. Wir stellen vor – Molzym-Synovial Test". 2011-11-01
WFB Wirtschaftsförderung Bremen GmbH. (11/9/09). "Pressemitteilung: Bindeglied zwischen Wissenschaft und angewandter Medizin. Kooperationszentrum Medizin etabliert sich". Bremen. 2009-11-09
WFB Wirtschaftsförderung Bremen GmbH. (11/9/09). "Pressemitteilung: Bremer Life Sciences-Unternehmen stellen sich vor. WFB und BIS unterstützten Life Sciences-Forum". Bremen. 2009-11-09
WFB Wirtschaftsförderung Bremen GmbH. (11/9/09). "Pressemitteilung: Neue Methode zur Labordiagnostik bei Krebserkrankungen. Tumortherapie – besser wissen, was wirkt". Bremen. 2009-11-09
WFB Wirtschaftsförderung Bremen GmbH. (4/13/10). "Pressemitteilung: Die WFB Wirtschaftsförderung Bremen teilt mit. Innovationsförderung neu ausgerichtet – Luft- und Raumfahrt, Eneuerbare Energien und Maritime Wirtschaft im Fokus". Bremen. 2010-04-13
WFB Wirtschaftsförderung Bremen GmbH. (5/10). "Pressemitteilung: Projekt des Monats. Wir stellen vor – Phtyolutions GmbH – Algen als erneuerbare Energie". Bremen. 2010-05-01
WFB Wirtschaftsförderung Bremen GmbH. (9/10). "Pressemitteilung: Projekt des Monats. Wir stellen vor – Omnilab Laborzentrum – FoodALYT". 2010-09-01
WFB Wirtschaftsförderung Bremen GmbH. (9/24/10). "Pressemitteilung: Bremen und Bremerhaven auf der Biotechnica 2010". 2010-09-24
White & Chase. (12/27/11). "Pressemitteilung: White & Chase berät Banken bei Refinanzierung von Qiagen". München. 2011-12-27
Wilex AG. (1/13/16). "Press Release: Wilex’s Partner Link Health Submits IND Application for Clinical Phase I with the uPA inhibitor Mesupron in China". Munich. 2016-01-13
Wilex AG. (1/18/12). "Press Release: Wilex Successfully Completed Phase I Study in Healthy Volunteers with the Oral MEK Inhibitor WX-554". Munich. 2012-01-18
Wilex AG. (1/25/17). "Press Release: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement". Munich. 2017-01-25
Wilex AG. (1/29/14). "Press Release: Wilex AG Plans Extensive Cost-cutting Measures. Focus on Contract Research and ADC Technology". Munich. 2014-01-29
Wilex AG. (1/9/12). "Press Release: Wilex AG Resolves Rights Issue Using Authorised Capital [Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)]". Munich. 2012-01-09
Wilex AG. (10/10/11). "Press Release: Wilex Inc. and ALPCO Diagnostics Sign Marketing and Distribution Agreement for North America". Munich & Salem, NH. 2011-10-10
Wilex AG. (10/10/13). "Press Release: Wilex Publishes 9-Months Financial Report 2013". Munich. 2013-10-10
Wilex AG. (10/11/12). "Press Release: Wilex AG Publishes 9-months Financial Report 2012". Munich. 2012-10-11
Wilex AG. (10/13/09). "Press Release: Wilex Releases 9-month Financial Report 2009. Significant Progress in Development Projects". Munich. 2009-10-13
Wilex AG. (10/13/10). "Presentation 9-Month Financial Report 2010. 13 October 2010". Munich. 2010-10-13
Wilex AG. (10/13/10). "Press Release: Wilex Publishes 9-Month Financial Report 2010. Mandatory Offer from dievini Hopp BioTech Closed". Munich. 2010-10-13
Wilex AG. (10/13/11). "Press Release: Wilex Publishes 9-Month Financial Report 2011". Munich. 2011-10-13
Wilex AG. (10/13/16). "Press Release: Interim Management Statement on the First Nine Months of 2016". Munich. 2016-10-13
Wilex AG. (10/14/14). "Press Release: Wilex Subsidiary Heidelberg Pharma Extends Research Collaboration with Roche". Munich. 2014-10-14
Wilex AG. (10/15/11). "Press Release: Wilex Reports an Adjustment of the Goodwill of Heidelberg Pharma AG According to IFRS". Munich. 2011-10-15
Wilex AG. (10/15/14). "Press Release: Wilex Publishes 9-Month Financial Report". Munich. 2014-10-15
Wilex AG. (10/16/12). "Press Release: Wilex AG Announces Results of Phase III ARISER Study with Rencarex in Clear Cell Renal Cell Carcinom. Trial Did Not Meet Its Primary Endpoint of Median Disease-free Survival (DFS)". Munich. 2012-10-16
Wilex AG. (10/2/09). "Press Release: Wilex Receives Approval for Phase I Trial with MEK Inhibitor WX-554". Munich. 2009-10-02
Wilex AG. (10/26/12). "Press Release: Letter to Shareholders". 2012-10-26
Wilex AG. (10/26/16). "Press Release: Wilex AG. Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)". Munich. 2016-10-26
Wilex AG. (10/5/11). "Press Release: FDA Grants Fast Track Designation to Wilex’s Rencarex for the Adjuvant Therapy of Clear Cell Renal Carcinoma". Munich. 2011-10-05
Wilex AG. (10/9/17). "Press Release: Interim Management Statement for the First Nine Months of 2017". Munich. 2017-10-09
Wilex AG. (10/9/17). "Press Release: Wilex AG Announces Adjustment of Guidance [Ad-hoc release – Insider information pursuant to Article 17 MAR]". Ladenburg. 2017-10-09
Wilex AG. (11/11/09). "Press Release: Wilex AG Resolves Capital Increase Using Authorised Capital". Munich. 2009-11-11
Wilex AG. (11/13/09). "Bezugsangebot [Kapitalerhöhung unter Ausnutzung des Genehmigten Kapitals]. Nicht zur Verteilung, Veröffentlichung oder Weiterleitung in den USA, Kanda, Japan und Australien". München. 2009-11-13
Wilex AG. (11/17/09). "Press Release: Wilex Starts Phase I Trial for WC-554 and Thereby Achieves Second Milestone of the Strategic Alliance with UCB". Munich. 2009-11-17
Wilex AG. (11/17/10). "Press Release: Wilex Acquires Oncogene Science Assets from Siemens Healthcare Diagnostics. Strategic Addition to Wilex’s Leading IP Portfolion in CA IX and uPA – Commerical Business with Product Revenues in Companion Diagnostics". 2010-11-17
Wilex AG. (11/21/11). "Press Release: Wilex AG. ARISER Independent Data Monitoring Committee (IDMC) Recommends Conducting the Final Analysis of the Pivotal Phase III Trial with Rencarex". Munich. 2011-11-21
Wilex AG. (11/23/15). "Press Release: Wilex AG Unveils Financing Strategy for Further Development of ADC Technology and Adopts Capital Measures". Munich. 2015-11-23
Wilex AG. (11/23/15). "Press Release: Wilex Publishes 9-month Financial Report". Munich. 2015-11-23
Wilex AG. (11/25/09). "Press Release: Wilex AG – Capital Increase. Subscription Price for New Wilex Shares Fixed at EUR 4.10". Munich. 2009-11-25
Wilex AG. (11/3/10). "Press Release: Wilex AG Announces Acquisition of Heidelberg Pharma AG. Access to Novel Antibody Drug Conjugate Platform Technogy for Therapeutic Antibodies in Cancer Treatment". Munich. 2010-11-03
Wilex AG. (11/7/13). "Press Release: Wilex Regains US Rights for Rencarex from Prometheus". Munich. 2013-11-07
Wilex AG. (12/12/12). "Press Release: Wilex Inc. Signs Distribution Agreement with Immundiagnostik AG for D-A-CH Region". Munich & Bensheim. 2012-12-12
Wilex AG. (12/17/10). "Press Release: Wilex AG Secures Further Financing with Shareholder Loans". Munich. 2010-12-17
Wilex AG. (12/3/09). "Press Release: Wilex AG Closes Capital Increase". Munich. 2009-12-03
Wilex AG. (12/4/12). "Press Release: Wilex AG Announces Restructuring". Munich. 2012-12-04
Wilex AG. (12/7/11). "Press Release: Wilex Inc. Lists Oncogene Science CA IX IHC Kit as an In-vitro Diagnostic with the FDA". Cambridge, MA & Munich. 2011-12-07
Wilex AG. (12/9/15). "Press Release: Wilex AG Successfully Completes Capital Increases". Munich. 2015-12-09
Wilex AG. (2/1/12). "Press Release: Wilex AG Successfully Completes Rights Issue (Ad-hoc release pursuant to $15 Wertpapierhandelsgesetz)". Munich. 2012-02-01
Wilex AG. (2/2/16). "Press Release: US Patent Office Granted Patent for Amatoxin Conjugates for Tumour Therapy". Munich. 2016-02-02
Wilex AG. (2/24/10). "Press Release: Presentation. Press and Analyst Conference – 24 February 2010". Munich. 2010-02-24
Wilex AG. (2/24/10). "Press Release: Wilex Reports on the Successful Financial Year 2009". Munich. 2010-02-24
Wilex AG. (2/24/14). "Press Release: Professor Olaf G. Wilhelm Leaves the Executive Management Board on 31 March 2014, Dr Jan Schmidt-Brand Will Lead the Company". Munich. 2014-02-24
Wilex AG. (2/28/12). "Press Release: Wilex Reports on a Successful Financial Year 2011". Munich. 2012-02-28
Wilex AG. (2/6/12). "Press Release: Wilex Receives Funding from the German Federal Ministry of Education and Research for the Development of WX-037 as Part of the »m4 Cluster Initiative«". Munich. 2012-02-06
Wilex AG. (2/6/17). "Press Release: Wilex AG Secures Financing Commitment from Its Main Shareholder Dievini". Munich. 2017-02-06
Wilex AG. (3/20/13). "Press Release: Wilex Inc. and Nuclea Biotechnologies Inc. Announce Cooperation". Munich & Pittsfield. 2013-03-20
Wilex AG. (3/22/16). "Press Release: Wilex Announces Financial Figures for the 2015 Financial Year and Reports on Course of Business". Munich. 2016-03-22
Wilex AG. (3/23/10). "Press Release: Wilex AG Secures Financing Up to EUR 20 Million through an Equity Line". Munich. 2010-03-23
Wilex AG. (3/26/15). "Press Release: Wilex Announces Financial Figures for the 2014 Financial Year and Reports on Course of Business". Munich. 2015-03-26
Wilex AG. (3/28/14). "Press Release: Wilex Enters into Licensing and Development Partnership for Mesupron in China with Link Health Group". Munich & Guangzhou. 2014-03-28
Wilex AG. (3/31/14). "Press Release: Wilex Announces Financial Figures for the 2013 Financial Year and Reports on Course of Business". Munich. 2014-03-31
Wilex AG. (4/10/14). "Press Release: Wilex AG Plans Reduction of Share Capital. Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)". Munich. 2014-04-10
Wilex AG. (4/12/12). "Press Release: Wilex Publishes Financial Report for the First Quarter of 2012. Rights Issue Successfully Concluded – Process for Final Analysis of Rencarex Started – Revenue and Earnings Improved". Munich. 2012-04-12
Wilex AG. (4/12/17). "Press Release: Interim Management Statement on the First Three Months of 2017". Munich. 2017-04-12
Wilex AG. (4/14/10). "Press Release: Presentation 3-Month Financial Report. 14 April 2010". Munich. 2010-04-14
Wilex AG. (4/14/10). "Press Release: Wilex Publishes 3-Month Financial Report 2010 and Reports Improved Results for the Period". Munich. 2010-04-14
Wilex AG. (4/14/14). "Press Release: Wilex Published 3-Month Financial Reports 2014". Munich. 2014-04-14
Wilex AG. (4/24/17). "Press Release: Wilex AG Plans Rights Issue Using Authorised Capital. Ad-hoc release [Not for distribution, publication or transmission in the USA, Canada, Japan and Australia]". Munich. 2017-04-24
Wilex AG. (4/25/16). "Press Release: Wilex AG Successfully Completes Capital Increase". Munich. 2016-04-25
Wilex AG. (4/8/15). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. 2015-04-08
Wilex AG. (5/3/10). "Press Release: Final Phase II Data of Mesupron Confirm Impressive Increase in Overall Survival of Patients with Pancreatic Cancer". Munich. 2010-05-03
Wilex AG. (6/14/12). "Press Release: Mesupron Met Its Primary Objective of Demonstrating Efficacy in the Proof of Concept Phase II Breast Cancer Trial". Munich. 2012-06-14
Wilex AG. (6/19/17). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates". Munich. 2017-06-19
Wilex AG. (6/2/16). "Press Release: Wilex AG Announces Change on the Executive Management Board". Munich. 2016-06-02
Wilex AG. (6/30/14). "Press Release: Wilex and RedHill Biopharma Enter into an Exclusive License Agreement for Mesupron". Munich & Tel Aviv. 2014-06-30
Wilex AG. (7/10/13). "Press Release: UCB Gets Access to Rights for an Antibody Programme from Wilex for Non-oncology Indications". Munich & Brussels. 2013-07-10
Wilex AG. (7/11/13). "Press Release: Wilex Publishes Half-yearly Financial Report 2013". Munich. 2013-07-11
Wilex AG. (7/12/12). "Press Release: Wilex Announces Results of Successful First Half Year 2012". Munich. 2012-07-12
Wilex AG. (7/13/17). "Press Release: Wilex Reports on First Half-year". Munich. 2017-07-13
Wilex AG. (7/14/15). "Press Release: Wilex Publishes Half-yearly Financial Report". Munich. 2015-07-14
Wilex AG. (7/15/10). "Press Release: Wilex AG Receives Tender Offer for a Mandatory Takeover Bid by dievini Hopp BioTech holding". Munich. 2010-07-15
Wilex AG. (7/15/14). "Press Release: Wilex AG Successfully Completes Capital Reduction. Reverse 4:1 Share Split Reduces Number of Outstanding Shares from 31.3 Million to 7.8 Million". Munich. 2014-07-15
next pagenext page 1 2 3 ... 168 169 170  next pagenext page



Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

» top